Hjem › Kronisk lymfatisk leukemi › Pennsylvania › Pittsburgh
Kliniske studier for Kronisk lymfatisk leukemi i Pittsburgh, PA
10 studier for Kronisk lymfatisk leukemi søker deltakere på steder i og rundt Pittsburgh (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
RekruttererFase 3
- West Penn Hospital, Pittsburgh
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
RekruttererFase 3
- Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
RekruttererFase 3
- Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
RekruttererFase 2
- UPMC Hillman Cancer Center, Pittsburgh
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
RekruttererFase 2
- UPMC Hillman Cancer Center, Pittsburgh
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
RekruttererFase 1/2
- Research Site, Pittsburgh
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
RekruttererFase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
RekruttererFase 3
- UPMC Hillman Cancer Center, Pittsburgh
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
RekruttererFase 2
- UPMC Hillman Cancer Center, Pittsburgh
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
RekruttererFase 2
- AHN Cancer Institute - West Penn Hospital, Pittsburgh
Kronisk lymfatisk leukemi-studier i andre byer
- Boston, MA31 studier
- Columbus, OH28 studier
- Durham, NC27 studier
- Washington, DC22 studier
- Seattle, WA20 studier
- Rochester, MN18 studier
- New York City, NY18 studier
- Houston, TX17 studier
- Baldwin Park, CA16 studier
- Milwaukee, WI15 studier
- Chicago, IL14 studier
- Cincinnati, OH14 studier
Andre studier i Pittsburgh
- Ikke-småcellet lungekreft48 studier
- Kreft (alle typer)41 studier
- Brystkreft39 studier
- Kolorektal kreft32 studier
- Metastatisk kreft31 studier
- Melanom31 studier
- Eggstokkreft30 studier
- Endometriekreft23 studier
- Prostatakreft23 studier
- Lungekreft23 studier
- Plateepitelcancer i hode og hals22 studier
- Slag22 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.